Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised

- PMLiVE

J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma

The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse

- PMLiVE

Astellas announces EC approval of Xtandi for expanded prostate cancer use

Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years

- PMLiVE

AI drug discovery biotech Xaira Therapeutics launches with over $1bn in committed funding

The company combines machine learning, data generation and therapeutic product development

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

FDA grants Day One’s Ojemda accelerated approval for paediatric low-grade glioma

The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population

- PMLiVE

Current trends and the renaissance of Alzheimer’s drug development

With 14 million people in Europe expected to suffer from Alzheimer’s and other forms of dementia by 2030, the race is on to find a treatment to not only slow...

- PMLiVE

Showing Deep Expertise at ONS

The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

Medscape Education Global

- PMLiVE

MEDSCAPE’S NEW AGE OF CERTAINTY FOR CME

The CME industry is changing. More than ever, activities need to be prioritized and measured to increase their impact on patient outcomes. Improving patient outcomes is the core objective for...

Medscape Education Global

- PMLiVE

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research Partnership

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

Incyte announces agreement to acquire Escient Pharmaceuticals for $750m

The deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links